NIH Support of Conferences and Scientific Meetings

NIH 对会议和科学会议的支持

基本信息

批准号：
8459141
负责人：
KATHELEEN GARDINER
金额：
$ 1.5万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-03-01 至 2014-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8459141
关键词：
Area Assimilations Basic Science Behavioral Biological Models Birth Brain Cell Line Chromosomes Chromosomes, Human, Pair 21 Clinical Research Clinical Trials Cognition Cognitive Cognitive deficits Collaborations Communication Development District of Columbia Down Syndrome Fostering Funding Genes Goals Human Human Chromosomes Informatin Intellectual functioning disability Lead Learning Memory impairment Molecular Participant Pharmaceutical Preparations Pharmacological Treatment Pharmacology Phenotype Regimen Request for Applications Research Research Personnel Role Sampling Severities Therapeutic Time Translational Research United States National Institutes of Health base biological systems combinatorial drug efficacy efficacy testing gene function induced pluripotent stem cell insight interest meetings mouse Ts65Dn mouse model novel postnatal prevent public health relevance response success symposium

Area Assimilations Basic Science Behavioral Biological Models Birth Brain Cell Line Chromosomes Chromosomes, Human, Pair 21 Clinical Research Clinical Trials Cognition Cognitive Cognitive deficits Collaborations Communication Development District of Columbia Down Syndrome Fostering Funding Genes Goals Human Human Chromosomes Informatin Intellectual functioning disability Lead Learning Memory impairment Molecular Participant Pharmaceutical Preparations Pharmacological Treatment Pharmacology Phenotype Regimen Request for Applications Research Research Personnel Role Sampling Severities Therapeutic Time Translational Research United States National Institutes of Health base biological systems combinatorial drug efficacy efficacy testing gene function induced pluripotent stem cell insight interest meetings mouse Ts65Dn mouse model novel postnatal prevent public health relevance response success symposium

展开

项目摘要

DESCRIPTION (provided by applicant): Down syndrome (DS) is characterized by specific learning/memory (L/M) deficits and brain abnormalities. Many of these features develop after birth, suggesting the possibility of effective postnatal therapeutics to prevent their onset or reduce their severity. This goal is supported by recent successes, with several pharmacological treatments, in rescuing L/M deficits in the Ts65Dn mouse model of DS. Extending these observations to safe, effective human clinical trials requires assimilation of functional informatin on chromosome 21genes, detailed understanding of the DS cognitive phenotype, use of appropriate model systems to test efficacy of drugs prior to human trials, and exploration of a broad range of pharmacological regimens in order to identify those of the greatest potential. No conference focusing on basic, clinical and translational research for intellectual disability in DS has been held in approximately 5 years. This application requests funding to cover expenses for a conference to bring together investigators from these diverse research areas. Participants will include established DS and non-DS investigators whose research directly or indirectly informs aspects of the DS cognitive phenotype and/or responses of these features to pharmacological therapy. The meeting will be held for three days in Washington DC in April 2013. It is anticipated that this conference will lead to new hypotheses regarding pharmacological treatment of cognitive deficits in DS, foster new collaborations and bring new researchers with novel expertise into the field of DS.

描述（由申请人提供）：唐氏综合症（DS）的特征是特定的学习/记忆（L/M）缺陷和脑异常。这些特征中的许多特征在出生后发展，这表明有效的产后治疗剂可以防止其发作或减轻其严重程度。该目标得到了最近的成功（几种药理治疗）的支持，并在DS的TS65DN小鼠模型中挽救L/M缺陷。将这些观察结果扩展到安全，有效的人类临床试验，需要在21GENES染色体上吸收功能性信息，对DS认知表型的详细了解，使用适当的模型系统在人类试验之前测试药物的功效，并探索广泛的药理方案，以确定具有最大潜力的药物。没有会议重点介绍DS中智障的基本，临床和转化研究已在大约5年内举行。该申请要求资金支付会议的费用，以将这些不同研究领域的调查人员汇集在一起。参与者将包括已建立的DS和非DS研究人员，他们的研究直接或间接地为DS认知表型和/或这些特征对药理学治疗的反应提供了信息。该会议将于2013年4月在华盛顿特区举行三天。预计，该会议将导致有关DS认知缺陷的药理学治疗，培养新的合作，并将具有新专业知识的新研究人员带入DS领域。